Roxana Botea is the new Country Director of Janssen Romania

With over 16 years of experience in the pharmaceutical industry, Roxana is the first woman to be appointed to the role of Country Director for Janssen Romania. Roxana is returning to Romania after nine years and after holding important roles in Sweden, Denmark, and Belgium, where she managed complex cross-functional teams and coordinated projects to support patients worldwide.

“I am returning in Romania with a strong motivation and a clear mission to contribute to improving the quality of life for Romanian patients. Along with a talented and experienced team, we continue to bring new medicines and indications in therapeutic areas with serious medical needs such as blood cancers, solid tumors, rare diseases, autoimmune diseases, and psychiatric conditions, so that Romanian patients can have access to innovative therapies.

This year, Janssen Romania celebrates 30 years of medical innovation for patients in our country and throughout this time, we have been a constant partner in the development of the healthcare system. All of our efforts will continue to be directed towards ensuring a better environment for Romanian patients through access to medical innovation, open dialogue with Romanian authorities and healthcare professionals, as well as through our social involvement.” says Roxana Botea, Country Director of Janssen Romania.

Janssen’s portfolio covers six therapeutic areas in Romania, for a range of serious conditions in hematology, oncology, psychiatry and neuroscience, immunology, infectious diseases, cardiovascular and metabolic diseases, and pulmonary hypertension. Over the years, Janssen Romania has been and continues to be a member of the main business and pharmaceutical industry associations, such as: the Romanian Association of International Medicines Manufacturers (ARPIM), the Local American Working Group (LAWG), the American Chamber of Commerce in Romania (AmCham), the Foreign Investors Council (FIC), the Chamber of Commerce of Belgium and Luxembourg in Romania and Moldova (BEROCC), and the Aspen Institute Romania.

In 2023, the Janssen Pharmaceutical Companies of Johnson & Johnson celebrates 30 years of medical innovation for Romanian patients. The company has evolved alongside the needs in healthcare and over the years has developed patient support programs and contributed to improving access to innovative medical therapies for Romanians. Among the company’s strategic initiatives are partnerships with the University of Medicine and Pharmacy “Carol Davila” in Bucharest (UMFCD), Hackathon4Health, the largest and most important annual project aimed at accelerating progress and innovation in digital health, now in its 7th edition, as well as the WiSTEM2D program, which encourages girls and women to engage in science, technology, engineering, math, manufacturing, and design. The last-mentioned program has already involved over 25,000 students, 470 teachers, and over 300 schools from 152 different areas of the country in the past 5 years.


About the Janssen Pharmaceutical Companies of Johnson & Johnson

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. For more information, visit and Follow Janssen Romania at @JanssenRomania.